Jersey City-based Organon is expanding its distribution and promotion agreement with Eli Lilly and Co. for migraine medicine Emgality.

Emgality, a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP), is used for the treatment of migraines in adults.

Announced Aug. 20, the new agreement builds on a previous partnership between the two organizations: Organon has served as the sole distributor and promoter of Emgality in Europe since February 2024. Following this deal, the company will become the sole distributor and promoter for Emgality in: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudia Arabia, Taiwan, Turkey and United Arab Emirates.

“The broadening of this agreement is a testament to Organon’s best-in-class commercialization capabilities, global footprint, and deep expertise in women’s health,” said Organon CEO Kevin Ali. “We know that migraine ranks as the leading cause of disability among young women and we’re proud to expand our offering to more women and men around the world living with episodic or chronic migraine.”

Under the terms of the agreement, Eli Lilly will receive an upfront payment of $22.5 million as well as sales-based milestone payments. It will also remain the marketing authorization holder as well as manufacture the product for sale.

“We are thrilled to expand this collaboration agreement with Organon,” said Ilya Yuffa, executive vice president of Eli Lilly and president of Lilly International. “We’re confident in our shared mission to bring this important migraine treatment to more patients around the world.”

See also:

In February, a smartphone-controlled therapeutic wearable made by Theranica became first non-pharmacological migraine treatment in the U.S. to receive commercial coverage policy. Click here to read more.